ATRA: atarabio.com Company Value to Net Income

Atara Biotherapeutics Inc - graphic logo of issuer ATRA

Atara Biotherapeutics (ATRA) is facing a shortage of rare reagents due to political tensions, which is hindering the certification of new drugs. Meanwhile, the business relies on an extensive network of US centers that ensures reliable transportation of biomaterials and high margins. The PE ratio is -5.90. The implementation of laboratory automation and data analysis software is made more evident by the daily price chart.

atarabio.com (ATRA) Price to Earnings Ratio: for the period 07/04/2022 - 11/12/2026

Analytical breakdowns for Atara Biotherapeutics, Inc. (ATRA)

- price and consensus price forecast:
Stock Price Atara Biotherapeutics Inc|ATRA - Consensus Target
- market capitalization information:
Market Value Atara Bio|ATRA - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Atara Biotherapeutics|ATRA - Company Book Value|Market Cap to Net Assets Ratio atarabio.com|ATRA - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Atara Biotherapeutics|ATRA - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Atara Biotherapeutics Inc|ATRA - Company Debts|Debt to Book Value Ratio Atara Bio|ATRA - Company Long-Term Debts|Short-Term Debt Atara Biotherapeutics|Quick Ratio atarabio.com
- earnings and market multiples details:
ATRA - Net Income|Future Net Profit Atara Biotherapeutics|ATRA - P/E Multiple|Forward P/E Multiple Atara Biotherapeutics Inc|ATRA - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Atara Bio|ATRA - Operating profit EBITDA|Net earnings per share (EPS TTM) Atara Biotherapeutics|ATRA - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months atarabio.com|ATRA - Earnings growth in current year|Net earnings per share growth forecast for next year Atara Biotherapeutics
Comprehensive company analysis:atarabio.com ATRA
Signature product of Atara Biotherapeutics, Inc.

Institutional capital evaluates Atara Biotherapeutics (ATRA) through the lens of the price-to-earnings ratio to determine the extent of the premium paid for future successes in cell therapy. By analyzing the P/E ratio dynamics of Atara Biotherapeutics (ATRA), investors can see how R&D biological risks impact the asset's fair value, allowing for an assessment of investment reliability regardless of economic cycles.

Key competitors

P/E Multiple argenx.com|Price to Earnings Ratio BNTX (BioNTech)|ABVX (ABIVAX) - Company Value to Net Income|P/E Multiple ADMA (ADMA Bio)|Business Payback Period Protagonist Corp (PTGX)|IMVT - Price to Earnings Ratio|kiniksa.com (KNSA) - Price to Earnings Ratio|Grifols (GRFS) - Price to Earnings Ratio|Price to Earnings Ratio Adaptive Biotech|Price to Earnings Ratio CLDX|P/E Multiple Aurinia Corp|Price to Earnings Ratio BioCryst (BCRX)|veratx.com - Price to Earnings Multiple|P/E Multiple DNTH (Dianthus Therapeutics, Inc.)|Pharvaris NV (PHVS) - Market Cap to Earnings|AbCellera Bio - P/E Multiple|TRML - P/E Multiple|PGEN (Precigen, Inc.) - Price to Earnings Ratio|PHAR: Market Price to Net Income Ratio|NKTR (Nektar Therapeutics Inc.) - P/E Multiple|P/E Multiple Upstream Bio, Inc.|Price to Earnings Ratio Zenas Biopharma, Inc. (ZBIO)|IMNM (Immunome Bio) - Company Value to Net Income|P/E Multiple GOSS (Gossamer Bio, Inc.)|P/E Multiple kalvista.com KALV|SEPN: Price to Earnings Ratio|Company Value to Net Income PVLA (Pieris Pharma)|SVRA: P/E Multiple|RIGL (Rigel Corp) - Price to Earnings Ratio|ANAB (AnaptysBio, Inc.) - P/E Multiple|astriatx.com (ATXS) - Business Payback Period|Price to Earnings Ratio enGene (ENGN)|RAPT - Market Cap to Earnings|Aerovate Therapeutics - Price to Earnings Ratio|Market Price to Net Income Ratio ACRS (Aclaris Therapeutics, Inc)|Kyverna Therapeutics - P/E Multiple|Company Value to Net Income TLSA (tizianalifesciences.com)|CABA: P/E Multiple|Market Cap to Earnings Ventyx Biosciences Inc. (VTYX)|Price to Earnings Ratio Theratechnologies Inc|AVTX: Company Value to Net Income|P/E Multiple ELDN|P/E Multiple agenusbio.com (AGEN)|Price to Earnings Ratio Climb Bio CLYM|ZURA (Zura Bio Ltd) - Market Cap to Net Income|aTyr - P/E Multiple|Market Cap to Earnings Adagene|IMA (ikenaoncology.com) - Price to Earnings Ratio|Shattuck Labs (STTK) - P/E Multiple|Price to Earnings Ratio EQ|CNTB (Connect Pharma) - Market Price to Net Income Ratio|P/E Multiple IMUX|Business Payback Period inflarx.de|P/E Multiple XFOR (X4 Pharmaceuticals)|ACET - Price to Earnings Ratio|CELU - Price to Earnings Ratio|Business Payback Period INmune Bio Inc INMB|BRNS: P/E Multiple|Kezar Life Sciences Inc (KZR) - P/E Multiple|Price to Earnings Ratio SABS|AKTX (akaritx.com) - Market Price to Net Income Ratio|Price to Earnings Ratio Enlivex Therapeutics (ENLV)|QTTB (q32bio.com) - Company Value to Net Income|P/E Multiple GOVX (GeoVax Labs Inc)|P/E Multiple Edesa Biotech Corp EDSA|IBIO - Price to Earnings Ratio|Market Cap to Net Income CARM|XTLB: P/E Multiple|Bolt Biotherapeutics, Inc. - Company Value to Net Income|HCWB (HCW Biologics, Inc.) - P/E Multiple|P/E Multiple Aptevo|Price to Earnings Ratio AIM ImmunoTech Inc. (AIM)|ADTX (aditxt.com) - Company Value to Net Income|Price to Earnings Ratio GRI Bio GRI|XRTX - Price to Earnings Ratio|ReShape Lifesciences - P/E Multiple|REVB - P/E Multiple|INDP (Indaptus Therapeutics) - Price to Earnings Ratio|scinai.com - Company Value to Net Income|CALI (CalciMedica Inc) - P/E Multiple|Affimed Therapeutics (AFMD) - Business Payback Period|Price to Earnings Ratio Allakos Inc. (ALLK)|Price to Earnings Ratio hookipapharma.com HOOK|Price to Earnings Ratio IGM Biosciences IGMS|ITOS - Price to Earnings Ratio|OCEA: Price to Earnings Ratio|TCBP - P/E Multiple|Third Harmonic Bio, Inc (THRD) - Price to Earnings Ratio